Study:
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Rationale:
n/a
Purpose:
A 2-part, Phase 1-2, open-label, parallel group, randomized study in patients with
Castration-Resistant Prostate Cancer (CRPC) who are no longer responding to treatment with
abiraterone and steroids. In Part A (Phase 1), patients will continue to receive the same
doses of abiraterone and steroids they were receiving prior to study entry and will be
randomized to receive 1 of 2 different treatment regimens of AT13387 in combination with
abiraterone. Once the best regimen is established in Part A, based on safety and antitumor
activity, patients will be randomized to the selected treatment regimen and dose of AT13387
in combination with abiraterone or AT13387 alone in Part B (Phase 2).
Study Status: Recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Prostate Cancer |
Drug: AT13387 and abiraterone
Drug: AT13387 alone |
Phase 1/Phase 2 |
Verified by
Astex Pharmaceuticals
April, 2013
Sponsored by: Astex Pharmaceuticals
Information provided by: Astex Pharmaceuticals
ClinicalTrials.gov identifier: NCT01685268
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic
Cleveland, Ohio 44195
United States
Johann De Bono, MD., Principal Investigator